Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases

Summary Effective systemic drugs are increasingly used to treat patients with colorectal liver metastases. Recent trials have shown that chemotherapy can reduce the size of metastases that are unresectable rendering them resectable, and decrease postoperative recurrence rates in patients with initia...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2009-03, Vol.10 (3), p.278-286
Main Authors: Chun, Yun Shin, MD, Laurent, Alexis, MD, Maru, Dipen, MD, Vauthey, Jean-Nicolas, Prof
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Chemotherapy
Clinical trials
Colorectal Neoplasms - pathology
Drugs
Fatty acids
Fatty Liver - chemically induced
Fatty Liver - therapy
Fluorouracil - adverse effects
Hematology, Oncology and Palliative Medicine
hepatotoxicity
Humans
Injuries
Insulin resistance
Lipid peroxidation
Liver
Liver - drug effects
Liver - pathology
Liver diseases
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Metastases
Metastasis
Mitochondria
Organoplatinum Compounds - adverse effects
Oxaliplatin
Oxidation
Pharmacogenetics
Reviews
Surgery
Time Factors
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Effective systemic drugs are increasingly used to treat patients with colorectal liver metastases. Recent trials have shown that chemotherapy can reduce the size of metastases that are unresectable rendering them resectable, and decrease postoperative recurrence rates in patients with initially resectable tumours. The increasing use of chemotherapy for colorectal liver metastases has raised awareness of the potential hepatotoxicities induced by systemic drugs and the effects of these drugs on outcome after hepatic resection. In this Review, we outline the rationale for the use of perioperative chemotherapy for colorectal liver metastases, associations between specific agents and patterns of liver injury, and strategies to treat patients with suspected or known chemotherapy-associated hepatotoxicity.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(09)70064-6